MedTrace Logo

MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

NCT00430352 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 545

Last updated 2017-08-14

Study results available
· View outcomes & findings →

Summary

This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

rituximab [MabThera/Rituxan]

375mg/m2 iv every 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-04
Primary Completion
2011-05-26
Completion
2011-05-26

Countries

  • Albania
  • Argentina
  • Australia
  • Bosnia and Herzegovina
  • Brazil
  • Bulgaria
  • Colombia
  • Croatia
  • Ecuador
  • Egypt
  • Finland
  • Germany
  • Greece
  • Israel
  • Italy
  • Mexico
  • Romania
  • Russia
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430352 on ClinicalTrials.gov